• 123 Citations
  • 6 h-Index
20082019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Ariella Hanker is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 9 Similar Profiles
Breast Neoplasms Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Disclosure Medicine & Life Sciences
Phosphatidylinositol 3-Kinases Medicine & Life Sciences
Monomeric GTP-Binding Proteins Medicine & Life Sciences
Emotions Medicine & Life Sciences
ras Proteins Medicine & Life Sciences
Growth Inhibitors Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2008 2019

  • 123 Citations
  • 6 h-Index
  • 4 Article
  • 3 Chapter
  • 2 Comment/debate
  • 2 Review article
6 Citations (Scopus)

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

Formisano, L., Lu, Y., Servetto, A., Hanker, A. B., Jansen, V. M., Bauer, J. A., Sudhan, D. R., Guerrero-Zotano, A. L., Croessmann, S., Guo, Y., Ericsson, P. G., Lee, K. M., Nixon, M. J., Schwarz, L. J., Sanders, M. E., Dugger, T. C., Cruz, M. R., Behdad, A., Cristofanilli, M., Bardia, A. & 11 others, O’Shaughnessy, J., Nagy, R. J., Lanman, R. B., Solovieff, N., He, W., Miller, M., Su, F., Shyr, Y., Mayer, I. A., Balko, J. M. & Arteaga, C. L., Dec 1 2019, In : Nature communications. 10, 1, 1373.

Research output: Contribution to journalArticle

Open Access
breast
inhibitors
cancer
Breast Neoplasms
Protein-Tyrosine Kinases
9 Citations (Scopus)

Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors

Hanker, A. B., Kaklamani, V. & Arteaga, C. L., Apr 1 2019, In : Cancer discovery. 9, 4, p. 482-491 10 p.

Research output: Contribution to journalReview article

Phosphatidylinositol 3-Kinases
Neoplasms
Drug-Related Side Effects and Adverse Reactions
Patient Selection
Cell Survival

Correction: HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2(Clin Cancer Res. (2017) 23:15 (4323-4334) DOI: 10.1158/1078-0432.CCR-16-2287)

Hanker, A. B., Garrett, J. T., Valeria Estrada, M., Moore, P. D., Ericsson, P. G., Koch, J. P., Langley, E., Singh, S., Kim, P. S., Frampton, G. M., Sanford, E., Owens, P., Becker, J., Groseclose, M. R., Castellino, S., Joensuu, H., Huober, J., Brase, J. C., Majjaj, S., Brohee, S. & 6 others, Venet, D., Brown, D., Baselga, J., Piccart, M., Sotiriou, C. & Arteaga, C. L., Feb 15 2019, In : Clinical Cancer Research. 25, 4, 1 p.

Research output: Contribution to journalComment/debate

Open Access
Disclosure
Emotions
Breast Neoplasms
Neoplasms
Therapeutics

Correction: Extracellular matrix/integrin signaling promotes resistance to combined inhibition of HER2 and PI3K in HER2 þ breast cancer (Cancer Research (2017) 77 (3280–3292) DOI: 10.1158/0008-5472.CAN-16-2808)

Hanker, A. B., Estrada, M. V., Bianchini, G., Moore, P. D., Zhao, J., Cheng, F., Koch, J. P., Gianni, L., Tyson, D. R., Sánchez, V., Rexer, B. N., Sanders, M. E., Zhao, Z., Stricker, T. P. & Arteaga, C. L., Feb 15 2019, In : Cancer Research. 79, 4, 1 p.

Research output: Contribution to journalComment/debate

Open Access
Disclosure
Phosphatidylinositol 3-Kinases
Integrins
Extracellular Matrix
Emotions
29 Citations (Scopus)

Genomic alterations of ERBB receptors in cancer: Clinical implications

Mishra, R., Hanker, A. B. & Garrett, J. T., Jan 1 2017, In : Oncotarget. 8, 69, p. 114371-114392 22 p.

Research output: Contribution to journalReview article

Open Access
Neoplasms
Non-Small Cell Lung Carcinoma
Mutation
Receptor Protein-Tyrosine Kinases
Phosphatidylinositol 3-Kinases